Tagged with

Switzerland Prof. Dr. med. Adriano Aguzzi provides insight on the past, present, and future of prion and antibody therapy research in Switzerland. The Institute of Neuropathology works closely with the University Hospital of Zurich to conduct their research. He also touches on translating research to industry and his spinoff ImmunoQure, which…

Health Professor Jürg Utzinger of the Swiss Tropical and Public Health Institute (Swiss TPH) emphasizes the importance of partnerships and sharing information for improving population health locally, nationally, and internationally. He comments on Swiss innovation, the clinical trials conducted at Swiss TPH, and the current publicity around the Zika virus.   You…

Pharma Daniel Breitenstein, VP and GM of GSK Switzerland, discusses the benefits of GSK’s three-part transaction with Novartis; the importance of respiratory diseases and vaccines for future success; and how the company has changed its business model by no longer paying for physicians to speak on their behalf, setting in process…

Pharma Janssen Switzerland’s Ludo Ooms highlights the strengths of the Swiss healthcare and life sciences sector including the efficiency of the government, a productive and well trained workforce, the national pricing system, and the climate for innovation; all factors which make Switzerland a strategic market for Johnson & Johnson and Janssen.…

Pharma This map shows the overall contribution of the pharmaceutical industry to the French economy, including number of employees by region, investment stats, and information on private sector research. Click here to download the latest free pharma report on France.

This chart shows the changes in the Top 10 global pharmaceutical markets since 2005 and up to 2018. Population increases and economic growth are increasing demand in emerging economies such as China and Brazil, while advanced markets like France and Italy are feeling the pinch of cost containment measures. For more…

Pharma Singapore, though conscious of its limitations, has been able to leverage its key assets of location, infrastructure and local talent in order to become the business hub for the entire region, with pharma and biotech as key components in its success. Singapore is … an attractive investment destination, especially for the…

Health Alberto Hechanova, president of the Drugstore Association of the Philippines (DSAP), discusses the competitive landscape of the country, highlighting the main challenges and opportunities for independent drugstores. In addition, he explains why being a member of the association can impact business success. Mr Hechanova, could you please introduce yourself and…

Pharma Daniel Pardo Bejarano, CEO of BOMI Mexico, details the competitive advantages and the unique business approach that make BOMI the logistics partner of choice of the Mexican healthcare industry, while the fast-growing company holds the ambition to double the size of its business over the next four years. After more…

Pharma With nearly €4 billion of capital investment in large molecule manufacturing underway, Ireland’s strategy to become a premier destination for biologics FDI has proven to be successful, according to BioPharmaChem Ireland director Matt Moran. Yet, Ireland today is much more than a manufacturing hub, and is well on its way to…

Pharma The following map shows the importance of the pharmaceutical industry to the highly regionalised Italian industry. Lombardy in the North of Italy employs 27,000 people in pharmaceuticals and is ranked number one for pharma and biotech firms. Click here to read more articles and interviews from Italy, and to download…

CEO and Associate Professor of the Singapore Clinical Research Institute (SCRI) Yee Leong Teoh explains the organization’s pivotal role in supporting and developing Singapore’s clinical research landscape, how these efforts have impacted studies from a regional perspective, and his outlook on what direction the country must now take to sustain its…